Target intelligence / Profile preview

Beta-site APP-cleaving enzyme 2 (BACE2)

Target: BACE2
Molecular classification: Enzyme, Aspartic Protease, Peptidase A1 protein family, Type I integral membrane glycoprotein

Overview

BACE2 is a type I integral membrane glycoprotein and an aspartic protease belonging to the peptidase A1 protein family. It is closely related to BACE1. It cleaves APP, influencing amyloid-beta peptide production and plays a role in melanosome formation, glucose homeostasis and endothelial function. Its involvement in Alzheimer's disease and Down syndrome is under investigation.

Other names: AEPLCALP56ASP1ASP21BAE2CDA13CEAP1DRAPbeta-secretase 2

Biological functions

APP ProcessingMelanosome MorphogenesisPigmentationGlucose HomeostasisPancreatic FunctionVascular Endothelium Regulation

Disease associations

Alzheimer’s DiseaseDown SyndromeType 2 Diabetes (potential)

Beyond the preview

Go deeper on Beta-site APP-cleaving enzyme 2 (BACE2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-site APP-cleaving enzyme 2 (BACE2).

Explore the full profile